无症状颈动脉狭窄的药物治疗与血运重建
研究包含两项平行、观察者盲法的临床试验,纳入155个中心、五个国家的高级别(≥70%)无症状颈动脉狭窄患者。支架试验(1245例)比较单纯强化药物治疗与支架置入+强化药物治疗;内膜剥脱试验(1240例)比较单纯强化药物治疗与内膜剥脱+强化药物治疗。主要终点为随机化至44天内的任何卒中或死亡,以及后续随访至4年内的同侧缺血性卒中。支架试验4年主要终点事件发生率:药物组6.0%(95%CI 3.8-8.3)vs 支架组2.8%(95%CI 1.5-4.3),绝对差异P=0.02;内膜剥脱试验:药物组5.3%(95%CI 3.3-7.4)vs 手术组3.7%(95%CI 2.1-5.5),绝对差异P=0.24,未达显著。结论:在无近期症状的高级别狭窄患者中,加用支架置入较单纯强化药物治疗降低4年复合终点风险,而颈动脉内膜剥脱术未带来显著获益。
要点
- 无症状≥70%颈动脉狭窄患者,强化药物治疗加颈动脉支架置入较单纯药物治疗降低4年主要终点事件(6.0% vs 2.8%,绝对差异P=0.02)。
- 同一人群中,强化药物治疗加颈动脉内膜剥脱术与单纯药物治疗相比,4年主要终点事件无显著差异(5.3% vs 3.7%,P=0.24)。
- 围手术期(0-44天)安全性:支架组发生7例卒中、1例死亡,药物组0例;内膜剥脱组9例卒中,药物组3例卒中。
- 研究纳入155个中心、五个国家的高级别(≥70%)无症状颈动脉狭窄患者,两项试验平行、观察者盲法设计。
适用人群与场景
- 高级别(≥70%)无症状颈动脉狭窄患者,来自155个中心、五个国家。
- 两项平行试验分别纳入支架试验1245例和内膜剥脱试验1240例。
诊断标准与关键阈值
- 颈动脉狭窄程度≥70%且无近期症状。
研究设计与关键结果
- 支架试验:4年主要终点事件发生率药物组6.0%(95%CI 3.8-8.3)vs 支架组2.8%(95%CI 1.5-4.3),绝对差异P=0.02。
- 内膜剥脱试验:4年主要终点事件发生率药物组5.3%(95%CI 3.3-7.4)vs 手术组3.7%(95%CI 2.1-5.5),绝对差异P=0.24。
- 0-44天:支架试验中药物组0例卒中或死亡,支架组7例卒中、1例死亡;内膜剥脱试验中药物组3例卒中,手术组9例卒中。
- 主要终点为随机化至44天内任何卒中或死亡,以及后续随访至4年内同侧缺血性卒中。
证据类型、等级与局限
- 证据类型:两项平行、观察者盲法临床试验(CREST-2,NCT02089217),由美国国家神经疾病与卒中研究所等资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于≥70%无症状颈动脉狭窄患者,在强化药物治疗基础上加用颈动脉支架置入可降低4年复合终点事件风险,而加用颈动脉内膜剥脱术未显示显著获益。
- 围手术期(0-44天)支架组发生7例卒中、1例死亡,药物组0例;内膜剥脱组9例卒中,药物组3例卒中,临床决策需权衡早期风险与长期获益。
指南或共识出处
- CREST-2临床试验,ClinicalTrials.gov注册号NCT02089217。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding revascularization to intensive medical management would provide greater benefit than intensive medical management alone is unclear.
METHODS: We conducted two parallel, observer-blinded clinical trials that enrolled patients with high-grade (≥70%) asymptomatic carotid stenosis across 155 centers in five countries. The stenting trial compared intensive medical management alone (medical-therapy group) with carotid-artery stenting plus intensive medical management (stenting group); the endarterectomy trial compared intensive medical management alone (medical-therapy group) with carotid endarterectomy plus intensive medical management (endarterectomy group). The primary outcome was a composite of any stroke or death, assessed from randomization to 44 days, or ipsilateral ischemic stroke, assessed during the remaining follow-up period up to 4 years.
RESULTS: A total of 1245 patients underwent randomization in the stenting trial and 1240 in the endarterectomy trial. In the stenting trial, the 4-year incidence of primary-outcome events was 6.0% (95% confidence interval [CI], 3.8 to 8.3) in the medical-therapy group and 2.8% (95% CI, 1.5 to 4.3) in the stenting group (P = 0.02 for the absolute difference). In the endarterectomy trial, the 4-year incidence of primary-outcome events was 5.3% (95% CI, 3.3 to 7.4) in the medical-therapy group and 3.7% (95% CI, 2.1 to 5.5) in the endarterectomy group (P = 0.24 for the absolute difference). From day 0 to 44, in the stenting trial, no strokes or deaths occurred in the medical-therapy group and seven strokes and one death occurred in the stenting group; in the endarterectomy trial, three strokes occurred in the medical-therapy group and nine strokes occurred in the endarterectomy group.
CONCLUSIONS: Among patients with high-grade stenosis without recent symptoms, the addition of stenting led to a lower risk of a composite of perioperative stroke or death or ipsilateral stroke within 4 years than intensive medical management alone. Carotid endarterectomy did not lead to a significant benefit. (Funded by the National Institute of Neurological Disorders and Stroke and others; CREST-2 ClinicalTrials.gov number, NCT02089217.).
参考来源
- Brott TG, Howard G, Lal BK, et al. Medical Management and Revascularization for Asymptomatic Carotid Stenosis. N Engl J Med. 2025. PMID: 41269206. doi:10.1056/NEJMoa2508800
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。